Clinical trial · Interventional
BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation
BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus CEM (Carboplatin, Etoposide, Melphalan) in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation
NCT05813132CI-TRIAL-00080467completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The proposed research aims to compare between BeEAM standard regimen and CEM as conditioning regimen in lymphoma patients in safety profile\& toxicity, infections (Febrile neutropenia) during transplant, time to engraftment (recovery not neutropenic), Length of stay at hospital, time to relapse, and other complications.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BEAM Protocol | Drug | — | UNRESOLVED |
| CEM protocol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- BeEAM Regimen
- description
- BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
- interventionNames
- Drug: BEAM Protocol
- type
- ACTIVE_COMPARATOR
- label
- CEM Regimen
- description
- CEM (Carboplatin, Etoposide, Melphalan)
- interventionNames
- Drug: CEM protocol
Primary outcomes (1)
- measure
- Incidence of Side Effects.
- timeFrame
- 3 month
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria 1\. Patients with lymphoma relapsed/refractory (RR) Hodgkin's lymphoma (HL) and non-Hodgkin lymphoma (NHL) with all subtypes. 2. Treat with conventional dose salvage regimens 3. Remission status before HSCT is complete remission (CR) or partial remission (PR). 4\. Age\>18 years. 5. Gender male and female. 6. CD34+ count cells \<2 ×106 CD34+ cells/kg BW. Exclusion Criteria 1. Remission status before HSCT is non remission (NR) or progressive disease (PD). 2. CD34+ count cells \<2 ×106 CD34+ cells/kg BW 3. CNS lymphoma or solid tumor not included in population. 4. Pregnancy or breast-feeding. 5. Any Psychological, familial, sociological, or geographical factor that interfere with patient adherence to medications. 6. History of allergy to any medications in both protocol
References
Publications (3)
- RESULTVelasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan;71(1):117-22. PMID 3334893
- RESULTFrankiewicz A, Sadus-Wojciechowska M, Najda J, Czerw T, Mendrek W, Sobczyk-Kruszelnicka M, Soska K, Ociepa M, Holowiecki J, Giebel S. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. Contemp Oncol (Pozn). 2018;22(2):113-117. doi: 10.5114/wo.2018.77046. Epub 2018 Jun 30. PMID 30150889
- DERIVEDEltelbanei MA, El-Bassiouny NA, Abdalla MS, Khalaf M, Werida RH. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation. BMC Cancer. 2024 Aug 13;24(1):1002. doi: 10.1186/s12885-024-12694-9. PMID 39134959